AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
Log in

NASDAQ:XBIOXenetic Biosciences Stock Price, Forecast & News

$1.02
+0.02 (+2.00 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.99
Now: $1.02
$1.02
50-Day Range
$0.93
MA: $1.03
$1.18
52-Week Range
$0.44
Now: $1.02
$13.68
Volume91,700 shs
Average Volume381,414 shs
Market Capitalization$6.41 million
P/E RatioN/A
Dividend YieldN/A
Beta2.47
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Read More
Xenetic Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XBIO
CUSIPN/A
CIKN/A
Phone781-778-7720

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20,000.00
Book Value$2.84 per share

Profitability

Net Income$-12,770,000.00

Miscellaneous

Employees4
Market Cap$6.41 million
Next Earnings Date8/20/2020 (Estimated)
OptionableNot Optionable

Receive XBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter.

Xenetic Biosciences (NASDAQ:XBIO) Frequently Asked Questions

How has Xenetic Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Xenetic Biosciences' stock was trading at $0.7031 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, XBIO stock has increased by 45.1% and is now trading at $1.02. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Xenetic Biosciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Xenetic Biosciences.

When is Xenetic Biosciences' next earnings date?

Xenetic Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 20th 2020. View our earnings forecast for Xenetic Biosciences.

How were Xenetic Biosciences' earnings last quarter?

Xenetic Biosciences Inc (NASDAQ:XBIO) released its quarterly earnings data on Thursday, May, 14th. The company reported ($0.19) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.37) by $0.18. The company earned $0.06 million during the quarter. View Xenetic Biosciences' earnings history.

What price target have analysts set for XBIO?

2 Wall Street analysts have issued 12-month price objectives for Xenetic Biosciences' stock. Their forecasts range from $2.00 to $2.50. On average, they anticipate Xenetic Biosciences' stock price to reach $2.25 in the next twelve months. This suggests a possible upside of 120.6% from the stock's current price. View analysts' price targets for Xenetic Biosciences.

Has Xenetic Biosciences been receiving favorable news coverage?

Media headlines about XBIO stock have been trending negative on Friday, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Xenetic Biosciences earned a coverage optimism score of -2.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news about Xenetic Biosciences.

Are investors shorting Xenetic Biosciences?

Xenetic Biosciences saw a decline in short interest in the month of June. As of June 15th, there was short interest totaling 302,300 shares, a decline of 7.1% from the May 31st total of 325,400 shares. Based on an average daily volume of 230,600 shares, the short-interest ratio is presently 1.3 days. Approximately 5.7% of the shares of the stock are sold short. View Xenetic Biosciences' Current Options Chain.

Who are some of Xenetic Biosciences' key competitors?

What other stocks do shareholders of Xenetic Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), Selecta Biosciences (SELB), Sorrento Therapeutics (SRNE), vTv Therapeutics (VTVT), Achieve Life Sciences (ACHV), Agile Therapeutics (AGRX), Aytu Bioscience (AYTU) and Biocept (BIOC).

Who are Xenetic Biosciences' key executives?

Xenetic Biosciences' management team includes the following people:
  • Mr. Jeffrey F. Eisenberg, CEO & Director (Age 53)
  • Mr. James F. Parslow, CFO, COO & Corp. Sec. (Age 54)
  • Dr. Curtis A. Lockshin, Chief Scientific Officer (Age 59)

What is Xenetic Biosciences' stock symbol?

Xenetic Biosciences trades on the NASDAQ under the ticker symbol "XBIO."

How do I buy shares of Xenetic Biosciences?

Shares of XBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Xenetic Biosciences' stock price today?

One share of XBIO stock can currently be purchased for approximately $1.02.

How big of a company is Xenetic Biosciences?

Xenetic Biosciences has a market capitalization of $6.41 million and generates $20,000.00 in revenue each year. Xenetic Biosciences employs 4 workers across the globe.

What is Xenetic Biosciences' official website?

The official website for Xenetic Biosciences is www.xeneticbio.com.

How can I contact Xenetic Biosciences?

Xenetic Biosciences' mailing address is 40 Speen Street Suite 102, Framingham MA, 01701. The company can be reached via phone at 781-778-7720 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.